Sunday 11 October 2026
Export all NVO data to Excel Powerpack
Novo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024. In the quarter to June 2026, revenue grew 4.47%, EPS fell 18.7%, free cash flow grew 71.6% and total debt rose 44.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for five.
38.64
0.46
+1.20%
Follow NVO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
11.72 | 8.63 | 14.66 | 16.13 |
+8 more quarters Free account |
P/S ratio |
4.13 | 3.20 | 4.83 | 5.28 | |
P/FCF ratio |
27.94 | 33.56 | 51.51 | 26.20 | |
P/Operating CF |
24.83 | 43.28 | 393.97 | 32.83 | |
P/B ratio |
6.18 | 5.13 | 7.69 | 9.27 | |
Price to Tangible BV |
13.77 | 14.25 | 23.33 | 24.88 | |
EV/Sales |
4.41 | 3.58 | 5.15 | 5.48 | |
EV/EBITDA |
8.57 | 6.86 | 10.63 | 11.22 | |
EV/Operating CF |
11.11 | 9.93 | 13.35 | 13.49 | |
EV/FCF |
29.81 | 37.45 | 54.86 | 27.18 | |
Quick Ratio |
0.66 | 0.56 | 0.57 | 0.57 | |
Current Ratio |
0.87 | 0.79 | 0.80 | 0.78 | |
Net Debt/EBITDA |
2.44 | 1.91 | 2.53 | 1.87 | |
Debt/Assets |
23.55% | 26.18% | 24.12% | 19.76% | |
Debt/Equity |
0.63 | 0.72 | 0.67 | 0.60 | |
Asset Turnover |
0.62 | 0.65 | 0.63 | 0.67 | |
Operating CF/Net income |
2.62 | 0.50 | 0.14 | 2.40 | |
Capex/Depreciation |
(1.24) | (3.40) | (8.45) | (2.04) | |
Interest Coverage |
18.04 | 17.04 | (22.99) | (15.50) | |
Research and Development Expense of Revenue |
22.66% | 10.62% | 18.11% | 20.53% | |
Selling, General and Administrative Expense of Revenue |
20.78% | 13.65% | 21.87% | 23.85% | |
Intangible Assets out of Total Assets |
0.21 | 0.23 | 0.24 | 0.21 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.12) | (0.17) | (0.12) | (0.10) | |
Graham Number |
26.73 | 26.20 | 22.72 | 21.52 | |
Earnings Yield |
8.53% | 11.59% | 6.82% | 6.20% | |
Free Cash Flow Yield |
3.58% | 2.98% | 1.94% | 3.82% | |
Revenue per Share |
2.75 | 3.41 | 2.78 | 2.64 | |
Operating CF per Share |
1.93 | 0.85 | 0.13 | 1.69 | |
Capex per Share |
(0.45) | (0.42) | (1.44) | (0.57) | |
Free Cash Flow per Share |
1.48 | 0.42 | (1.31) | 1.12 | |
Cash per Share |
1.71 | 0.91 | 1.15 | 1.48 | |
Shareholders Equity per Share |
7.76 | 7.16 | 6.61 | 5.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.76 | 7.16 | 6.61 | 5.98 | |
Free Cash Flow |
6,585.08 | 1,886.25 | (5,822.49) | 4,961.69 | |
Working Capital |
(4,728.22) | (7,491.90) | (6,541.70) | (8,217.58) | |
Capital Expenditures |
(1,979.80) | (1,885.31) | (6,396.29) | (2,552.86) | |
Net Current Asset Value |
(25,669.02) | (28,006.19) | (26,707.27) | (25,135.71) | |
EV/EBIT |
10.17 | 7.85 | 12.46 | 13.12 | |
Capex to Sales |
0.16 | 0.12 | 0.52 | 0.22 | |
Price to Operating Income |
9.53 | 7.04 | 11.70 | 12.64 | |
| Other line items | |||||
Average Receivables |
14,970.60 | 13,944.11 | 13,088.90 | 13,101.46 | |
Average Payables |
3,280.25 | 2,540.16 | 3,587.02 | 3,646.31 | |
Average Inventory |
7,467.02 | 7,044.14 | 6,718.01 | 6,516.04 | |
Average Assets |
82,954.15 | 78,297.39 | 74,867.82 | 69,403.55 | |
Average Common Equity |
29,996.77 | 25,673.99 | 25,092.09 | 22,185.33 |
Columns are period end dates